Cargando…
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
Autores principales: | Blaszczak, Alecia, Trinidad, John C.L., Cartron, Alexander M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151529/ https://www.ncbi.nlm.nih.gov/pubmed/32283230 http://dx.doi.org/10.1016/j.jaad.2020.04.030 |
Ejemplares similares
-
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
por: Kearns, Donovan G., et al.
Publicado: (2020) -
Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic
por: Shah, Monica, et al.
Publicado: (2020) -
Experience in patients with hidradenitis suppurativa and COVID-19 symptoms
por: Galán, José Luis, et al.
Publicado: (2020) -
Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa
por: Seltzer, Janyla A., et al.
Publicado: (2020) -
Treatment considerations for patients with pemphigus during the COVID-19 pandemic
por: Shakshouk, Hadir, et al.
Publicado: (2020)